Authors: Alexander Weimer MD, Shintaro Chiba MD
Regulatory Status
The DEXTER Robotic Surgery System received CE-Mark approval in Europe in December 2020. In the United States, the system received FDA De Novo authorization in the fourth quarter of 2024 for adult laparoscopic inguinal hernia repair. Subsequent FDA 510(k) clearances have expanded indications to include laparoscopic cholecystectomy and selected benign gynecologic procedures, including total laparoscopic hysterectomy with salpingectomy and/or oophorectomy. Clinical investigation for additional applications, including sacrocolpopexy and other general surgical indications, is ongoing.
Overview & Intended Use
DEXTER is designed with a compact footprint and open-architecture workflow to facilitate integration into existing operating rooms, including ambulatory surgery centers, while minimizing disruption to established laparoscopic practice.
In the United States, the system is FDA-cleared for adult patients (22 years and older) undergoing laparoscopic inguinal hernia repair, cholecystectomy, and selected benign gynecologic procedures. Under CE-Mark approval in Europe, indications include a broader range of urologic, general laparoscopic, and gynecologic procedures.
Technical Features and Differentiators
DEXTER incorporates several features intended to distinguish it from traditional robotic platforms. The surgeon console is sterile, allowing the surgeon to remain within the operative field and maintain direct patient access rather than operating from a remote, non-sterile station. This configuration may enhance team communication and patient access when needed.
The system emphasizes mobility and a small physical footprint, permitting deployment in existing operating rooms without structural modification and enabling movement between rooms to optimize utilization. A defining feature is its hybrid, on-demand workflow, which allows seamless transition between conventional laparoscopy and robotic instrument use without undocking.
DEXTER employs an open-architecture design compatible with all 5–10 mm endoscopes, including 4K and fluorescence imaging systems, and integrates with third-party imaging platforms, energy devices, vessel sealers, and standard laparoscopic trocars. This compatibility may reduce the need for proprietary peripheral equipment and preserve prior capital investments.
The platform utilizes fully wristed, single-use instruments designed to enhance dexterity and precision while eliminating reprocessing requirements. Published experience reports median docking times of approximately four minutes, with console times stabilizing after roughly 10–15 cases, suggesting a relatively short learning curve.
Collectively, these features are intended to expand access to robotic-assisted surgery, particularly in smaller hospitals and outpatient surgical centers.
Clinical Experience
Early clinical reports demonstrate feasibility across multiple procedures. An implementation study of 59 robotic cholecystectomies reported 100% procedural completion without device-related intraoperative deficiencies, a median operative time of 60 minutes, median docking time of five minutes, and rapid learning-curve stabilization (<15 cases) (Hotz).
A separate series of 47 robot-assisted radical prostatectomies reported successful completion without conversion or major technical failure, a median operative time of 198 minutes, and a median length of stay of two days (Robin).
Additional experience published in Life highlighted reduced docking complexity and preserved patient access compared with traditional robotic systems (Conrad). Early U.S. use following FDA clearance included successful outpatient inguinal hernia repairs within 30 days of authorization.
While early data demonstrate feasibility and favorable workflow characteristics, comparative effectiveness data versus established robotic platforms remain limited, and no large randomized trials are currently available.
Advantages
DEXTER’s sterile console and hybrid workflow allow flexibility while maintaining direct patient access, which may be valuable in complex or staged procedures. Its compact footprint supports deployment in ambulatory or space-constrained environments. Open-architecture compatibility may reduce incremental capital requirements, and early data suggest a relatively short learning curve, potentially facilitating adoption by institutions expanding robotic programs.
Limitations & Considerations
Although U.S. indications have expanded, they remain more limited than those of established multi-specialty robotic platforms. Comparative outcomes data remain sparse. The single-use instrument model may increase per-case consumable costs and warrants institution-specific financial analysis. Broader adoption in complex oncologic procedures requires further validation, and institutions should evaluate vendor support, training infrastructure, and long-term service agreements.
Summary & Perspective
The DEXTER system represents a workflow-focused approach to robotic-assisted surgery, emphasizing compact design, procedural flexibility, and compatibility with existing OR infrastructure. Early experience supports feasibility and efficiency, particularly in general and benign gynecologic procedures. Continued evaluation of outcomes, cost-effectiveness, and comparative performance will determine its long-term role within the evolving minimally invasive surgical landscape.
Figure X. DEXTER® Robotic Surgery System in use during a minimally invasive surgical procedure. Image courtesy of Distalmotion SA. *Reproduced with permission*
Introducing the DEXTER® Robotic Surgery System
*https://www.youtube.com/watch?v=5HVhxDhi3Ck*
Citations
Conrad PV, Mehdorn AS, Alkatout I, Becker T, Beckmann JH, Pochhammer J. The Combination of Laparoscopic and Robotic Surgery: First Experience with the Dexter Robotic System™ in Visceral Surgery. Life (Basel). 2024 Jul 12;14(7):874. doi: 10.3390/life14070874. PMID: 39063627; PMCID: PMC11277731.
Hotz AS, Seeger N, Gantner L, Grieder F, Breitenstein S. Implementation of a Robotic Surgical Program With the Dexter Robotic Surgery System: Initial Experiences in Cholecystectomy. World J Surg. 2025 May;49(5):1221-1227. doi: 10.1002/wjs.12531. Epub 2025 Mar 23. PMID: 40122784; PMCID: PMC12058442
Robin H, Hugues G, Fontanier T, Ali Benali N, Forgues A, Emeriau D, Mignot H, Thillou D. Perioperative and Short-Term Functional Outcomes of Robot-Assisted Radical Prostatectomy with the Dexter Robotic System. J Endourol. 2025 Sep;39(9):905-910. doi: 10.1089/end.2024.0763. Epub 2025 Jul 7. PMID: 40622890.